With ties to University of Arizona Tech Launch, RaeSedo is developing a new class of asthma therapeutics: novel analogues of naturally occurring lung proteins for treatment in patients with asthma and other respiratory diseases. Founded by a team of women-led physician-scientists with significant experience in clinical trials, patient care, and translational basic science research, RaeSedo organzies around developing new and improved structural peptidomimetics derived from active regions of SP-A in stable, inhaled forms that are as efficacious as endogenous SP-A in reducing inflammation in asthma and other lung diseases. Anchored in a decade of collaborative efforts, the RaeSedo team have demonstrated that a previously unknown region of activity within surfactant protein A (SP-A), an endogenous lung protein with innate immune properties, is as efficacious as the full-length oligomeric SP-A in reducing airway inflammation associated with asthma.
